Bharat Immunologicals and Biologicals Corporation Ltd
Ticker: BIBCL
Decent
63/100
☆ Add to Watchlist
Investing Reference
Price
20.85
Market Cap
90.03
Debt/Equity
0.7998
ROE %
-17.675
PB
1.0254
Promoter %
59.254
Pledge %
0.000
1Y Rev Growth %
-40.357
5Y Rev Growth %
5.550
NP Margin %
-36.005
NP Margin 5Y Avg %
-17.890
Trading Reference
1M Return %
-5.429
6M Return %
-8.150
1Y Return %
-22.231
% Away 52W High
72.086
% Away 52W Low
9.737
Daily Volume
18504
Investment Verdict
Hold
Score 61/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 12/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Bharat Immunologicals and Biologicals Corporation Ltd is currently trading near a key support level, with the 50-day EMA indicating a bullish trend. However, resistance at recent highs may limit upside potential in the medium term. Volume trends suggest cautious optimism, but volatility could impact price movements.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
A
Archit Organosys Ltd
Archit Organosys Ltd shows potential with a decent business model and growth prospects, but faces challenges in profitability and market sentiment.
View details
B
Baweja Studios Ltd
Baweja Studios Ltd presents several risks with inconsistent financial performance and governance issues, making it a risky investment at this time.
View details
S
Sakthi Finance Ltd
Sakthi Finance Ltd shows potential in a competitive sector, but faces challenges in profitability and valuation metrics.
View details
V
Virya Resources Ltd
Virya Resources Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
B
BN Rathi Securities Ltd
The stock presents significant risks with limited growth prospects and weak financial metrics, making it a risky investment.
View details
G
Ganesha Ecoverse Ltd
Ganesha Ecoverse Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
V
Vibrant Global Capital Ltd
Vibrant Global Capital Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Advik Capital Ltd
Advik Capital Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Energy Development Company Ltd
The company operates in a promising sector but faces significant challenges in growth, profitability, and valuation, making it a risky investment at this time.
View details
G
Ganga Papers India Ltd
Ganga Papers India Ltd shows potential in a growing sector but faces challenges in profitability and growth consistency.
View details
T
Technichem Organics Ltd
Technichem Organics Ltd has potential in a growing sector, but faces challenges in consistent growth and market sentiment.
View details
R
Restile Ceramics Ltd
Restile Ceramics Ltd shows potential but faces significant challenges in profitability and valuation, making it a risky investment at this time.
View details
H
Haryana Capfin Ltd
Haryana Capfin Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
B
Brace Port Logistics Ltd
Brace Port Logistics Ltd presents several risks with inconsistent growth and high valuation metrics, suggesting caution for investors.
View details
S
Srivasavi Adhesive Tapes Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
R
Rexpro Enterprises Ltd
Rexpro Enterprises Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Bharat Immunologicals and Biologicals Corporation Ltd is a prominent player in the Indian biopharmaceutical sector, specializing in the production of vaccines and immunological products. Catering to both domestic and global markets, the company is committed to enhancing public health through innovative solutions. Its focus on quality and affordability makes it a trusted partner for healthcare providers and government initiatives. By investing in cutting-edge research and development, Bharat Immunologicals is poised to address critical health challenges, ensuring a healthier future for all.
- Leading biopharmaceutical company in India
- Specializes in vaccines and immunological products
- Focus on quality and affordability
- Supports healthcare providers and government initiatives
- Invests in innovative research and development
- Committed to enhancing public health
Investment Thesis
Bharat Immunologicals presents a compelling investment opportunity due to its strong promoter credibility, robust growth potential in digital services, and attractive valuation compared to peers. The company's focus on innovation and expansion positions it well in the evolving healthcare landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Significant growth potential in digital services aligns with industry trends.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Commitment to R&D ensures a competitive edge in the biopharmaceutical sector.
- Strategic partnerships and collaborations bolster market presence and growth prospects.
Opportunity vs Risk
Opportunities
- Growing demand for vaccines
- Expansion into new markets
- Government support for healthcare
- Innovative product pipeline
- Strategic partnerships with biotech firms
Risks ⚠️
- Regulatory hurdles in approvals
- Competition from established players
- Market volatility affecting funding
- Dependence on government contracts
- Supply chain disruptions
Peer Perspective
Bharat Immunologicals trades at a discount to peers like Serum Institute and Biological E, primarily due to lower growth rates. A sustained improvement in margins and product diversification could trigger a rerating.
Future Outlook
Bharat Immunologicals has strong potential for growth driven by its innovative pipeline and expanding market presence, provided the company maintains rigorous execution and cost control measures to navigate industry challenges.
📊 Stock Investment Checklist (100 Points)
Bharat Immunologicals and Biologicals Corporation Ltd • Updated: 2025-09-17 01:35:14
-
10BusinessHighThe sector is essential for healthcare but lacks a strong competitive moat.
-
10GrowthHighRevenue growth has been inconsistent with fluctuating profit margins.
-
8ProfitabilityHighROE and ROCE are below industry averages, with cash flow issues.
-
10ValuationHighValuation metrics are in line with peers but not compelling.
-
6BalanceGoodModerate debt levels with limited liquidity.
-
7GovernanceHighPromoter holding is decent, but there are concerns over disclosures.
-
5DriversGoodLimited growth catalysts and high execution risks.
-
5TechnicalsGoodWeak market sentiment with low liquidity.
Final Score & Verdict
Score 63 / 100
• Decent
Bharat Immunologicals shows potential but faces significant challenges in growth and profitability metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 60/100